Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Food Allergy with Elevated IgE
NCT06934200Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in Food hypersensitivity, sponsored by Johns Hopkins University. Primary endpoint: Number of participants without dose limiting symptoms at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
omalizumab
03
Conditions
Food hypersensitivity
Beyond the preview
Go deeper on NCT06934200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934200.